Alizé Pharma III collects $1.94 mln
Alizé Pharma III SAS, a developer of biopharmaceutical products that treat metabolic disorders and rare diseases, has raised $1.94 million in funding. The investors included Sofimac Partners via their FCPI Emergence Innovation 1 seed capital fund, Octalfa, Sham Innovation Santé, Rhône-Alpes Création, Crédit Agricole Création, CEMA and TAB Consulting.
17 March 2015•6 mins read
